Oral Health Group

Straumann receives technology award


May 20, 2010
by ken

Straumann receives Frost & Sullivan Medical
Device Technology of the Year Award for Roxolid®

Basel, 18 May 2010:  At an official ceremony in London,
Straumann, a global leader in regenerative, restorative and replacement
dentistry, was presented with the 2009 ‘Medical Device Technology of the Year
Award’ for Roxolid®, an innovative high performance material for dental
implants. The Award, which recognizes excellence in technological innovation, is
one of the Best Practices Awards bestowed by Frost & Sullivan,the global
growth consulting company.

About
Roxolid

The material most commonly
used for dental implants today is titanium,which is well known for its
biological compatibility with the human body, its resistance to corrosion, and
its strength. However, its mechanical properties are limited in the case of
small diameter implants, which are needed in narrow spaces. Roxolid is an alloy
of titanium and zirconium which combines high tensile and fatigue strengths with
excellent osseointegration. It has been designed to increase reliability and
confidence with small diameter implants. Rigorous tests in Straumann
laboratories have shown that it has higher fatigue and tensile strength than
pure titanium (grade 4 annealed and cold worked), the current material of choice
for dental implants. In addition, preclinical study results have indicated that
bone integrated with Roxolid better than with pure titanium (grade 4).
Additionally, Roxolid can accommodate the sophisticated micro-structuring
processes required for Straumann’s SLActive® surface technology, which enhances
osseointegration.

Straumann’untitled.jpgs
largest prelaunch clinical program to date

Roxolid has been undergoing a broad program of clinical trials
in 9 countries, the first of which began m
ore than 2 years ago. Involving 60
centers and more than 300 patients, this is one of the largest clinical research
programs ever undertaken by a dental implant company prior to market launch.
Initial clinical reports have already been presented by lead investigators at
recent major congresses. Apart from the clinical program, Roxolid was made
available to 450 selected specialists in a controlled release program, in which
more than 11 000 implants were distribute
d.

To learn more about  Roxolid®, contact your Straumann
representative at 1-800-363-4024.  Further information about Roxolid is
available at http://www.straumann.com

 
About Frost &
Sullivan

Frost & Sullivan, the
Growth Partnership Company, partners with clients to accelerate their growth.
The company’s Growth Partnership Services and Growth Consulting services empower
clients to create a growth-focused culture that generates, evaluates, and
implements effective growth strategies. For nearly 50 years Frost & Sullivan
has partnered with Global 1000 companies, emerging businesses and the investment
community from more than 35 offices on six continents.

Frost & Sullivan Best Practices Awards recognize
companies in a variety of regional and global markets for demonstrating
outstanding achievement and superior performance in areas such as leadership,
technological innovation, customer service, and strategic product
development.

Reblog this post [with Zemanta]